[1]
Uttara B, Singh AV, Zamboni P, Mahajan R. Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options. Curr Neuropharmacol 2009; 7(1): 65-74.
[2]
Phaniendra A, Jestadi DB, Periyasamy L. Free radicals: properties, sources, targets, and their implication in various diseases. Indian J Clin Biochem 2015; 30(1): 11-26.
[3]
Wang X, Michaelis EK. Selective neuronal vulnerability to oxidative stress in the brain. Front Aging Neurosci 2010; 2: 12.
[4]
Friedman J. Why is the nervous system vulnerable to oxidative stress? In: Gadoth N, Göbel HH, Eds. Oxidative stress and free radical damage in neurology, oxidative stress in applied basic research and clinical practice. Humana Press 2010; pp. 19-27.
[5]
Sen S, Chakraborty R. The role of antioxidants in human health. in:
oxidative stress: diagnostics, prevention, and therapy. Vol 1083.
ACS Symposium Series. Am Chem Soc 2011: 1-37.
[6]
Peterson LJ, Flood PM. Oxidative stress and microglial cells in parkinson’s disease. Mediators Inflamm 2012; 2012401264
[7]
Kumar A, Alvarez-Croda D-M, Stoica BA, Faden AI, Loane DJ. Microglial/Macrophage polarization dynamics following traumatic brain injury. J Neurotrauma 2016; 33(19): 1732-50.
[8]
Morgan MJ, Liu Z. Crosstalk of reactive oxygen species and NF-κB signaling. Cell Res 2011; 21(1): 103-15.
[9]
Basser PJ, Mattiello J, LeBihan D. MR diffusion tensor spectroscopy and imaging. Biophys J 1994; 66(1): 259-67.
[10]
Aung WY, Mar S, Benzinger TL. Diffusion tensor MRI as a biomarker in axonal and myelin damage. Imaging Med 2013; 5(5): 427-40.
[11]
Cheng GK. Lin-C, John DC, Carlo P, Peter JB. A unifying theoretical and algorithmic framework for least squares methods of estimation in diffusion tensor imaging. J Magn Resonance 2006; 182(1): 115-25.
[12]
Song SK, Sun SW, Ramsbottom MJ, Chang C, Russell J, Cross AH. Dysmyelination revealed through MRI as increased radial (but unchanged axial) diffusion of water. Neuroimage 2002; 17(3): 1429-36.
[13]
Sun SW, Liang HF, Trinkaus K, Cross AH, Armstrong RC, Song S-K. Noninvasive detection of cuprizone induced axonal damage and demyelination in the mouse corpus callosum. Magn Reson Med 2006; 55(2): 302-8.
[14]
Sun SW, Liang HF, Cross AH, Song SK. Evolving wallerian degeneration after transient retinal ischemia in mice characterized by diffusion tensor imaging. Neuroimage 2008; 40(1): 1-10.
[15]
Hui ES, Fu Q, So K, Wu EX. Diffusion tensor MR study of optic nerve degeneration in glaucoma. Conf Proc IEEE Eng Med Biol Soc 2007; 2007: 4312-5.
[16]
Ashtari M, Cottone J, Ardekani BA, et al. Disruption of white matter integrity in the inferior longitudinal fasciculus in adolescents with schizophrenia as revealed by fiber tractography. Arch Gen Psychiatry 2007; 64(11): 1270-80.
[17]
Assaf Y, Pasternak O. Diffusion tensor imaging (DTI)-based white matter mapping in brain research: a review. J Mol Neurosci 2008; 34(1): 51-61.
[18]
Gilgun-Sherki Y, Melamed E, Offen D. The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy. J Neurol 2004; 251(3): 261-8.
[19]
Leterrier C, Dubey P, Roy S. The nano-architecture of the axonal cytoskeleton. Nat Rev Neurosci 2017; 18: 713.
[20]
Rochlin MW, Wickline KM, Bridgman PC. Microtubule stability decreases axon elongation but not axoplasm production. J Neurosci 1996; 16(10): 3236-46.
[21]
Fang C, Decker H, Banker G. Axonal transport plays a crucial role in mediating the axon-protective effects of NmNAT. Neurobiol Dis 2014; 68: 78-90.
[22]
Hirokawa N, Niwa S, Tanaka Y. Molecular motors in neurons: transport mechanisms and roles in brain function, development, and disease. Neuron 2010; 68(4): 610-38.
[23]
Wang MB. The axon: structure, function, and pathophysiology. Neurosurgery 1996; 38(3): 615-6.
[24]
Beaulieu C, Allen PS. Water diffusion in the giant axon of the squid: implications for diffusion weighted MRI of the nervous system. Magn Reson Med 1994; 32(5): 579-83.
[25]
Beaulieu C, Allen PS. Determinants of anisotropic water diffusion in nerves. Magn Reson Med 1994; 31(4): 394-400.
[26]
J.Z. Young. The structure of nerve fibres in cephalopods and crustacea. Proc R Soc Lond B 1936; 121(823): 319-37.
[27]
Grimm S, Hoehn A, Davies KJ, Grune T. Protein oxidative modifications in the aging brain: consequence for the onset of neurodegenerative disease. Free Radic Res 2011; 45(1): 73-88.
[28]
Cai ZL, Shi JJ, Yang YP, et al. MPP+ impairs autophagic clearance of alpha-synuclein by impairing the activity of dynein. Neuroreport 2009; 20(6): 569-73.
[29]
Johnston JA, Illing ME, Kopito RR. Cytoplasmic dynein/dynactin mediates the assembly of aggresomes. Cell Motil Cytoskeleton 2002; 53(1): 26-38.
[30]
Roediger B, Armati PJ. Oxidative stress induces axonal beading in cultured human brain tissue. Neurobiol Dis 2003; 13(3): 222-9.
[31]
Moseley ME, Cohen Y, Kucharczyk J, et al. Diffusion-weighted MR imaging of anisotropic water diffusion in cat central nervous system. Radiology 1990; 176(2): 439-45.
[32]
Fang C, Bourdette D, Banker G. Oxidative stress inhibits axonal transport: implications for neurodegenerative diseases. Mol Neurodegener 2012; 7: 29.
[33]
Lee CF, Liu CY, Hsieh RH, Wei YH. Oxidative stress-induced depolymerization of microtubules and alteration of mitochondrial mass in human cells. Ann N Y Acad Sci 2005; 1042: 246-54.
[35]
Salehi A, Wu C, Zhan K, Mobley WC. Axonal transport of neurotrophic signals: an achilles’ heel for neurodegeneration? In: George-Hyslop PHS, Mobley WC, Christen Y, Eds. Intracellular Traffic and Neurodegenerative Disorders Research and Perspectives in Alzheimer’s Disease Springer Berlin, Heidelberg.
[36]
Peters A, Vaughn JE. Microtubules and filaments in the axons and astrocytes of early postnatal rat optic nerves. J Cell Biol 1967; 32(1): 113-9.
[37]
Waxman SG, Kocsis JD, Stys PK. Axon: structure, function and pathophysiology - Oxford Scholarship. Published May 25 1995.
[39]
Busciglio J, Lorenzo A, Yeh J, Yankner BA. beta-amyloid fibrils induce tau phosphorylation and loss of microtubule binding. Neuron 1995; 14(4): 879-88.
[40]
Sun SW, Liang HF, Mei J, Xu D, Shi WX. In vivo diffusion tensor imaging of amyloid-β-induced white matter damage in mice. J Alzheimers Dis 2014; 38(1): 93-101.
[41]
Busciglio J, Lorenzo A, Yeh J, Yankner BA. beta-amyloid fibrils induce tau phosphorylation and loss of microtubule binding. Neuron 1995; 14(4): 879-88.
[42]
Aboitiz F, Rodríguez E, Olivares R, Zaidel E. Age-related changes in fibre composition of the human corpus callosum: sex differences. Neuroreport 1996; 7(11): 1761-4.
[43]
Marner L, Nyengaard JR, Tang Y, Pakkenberg B. Marked loss of myelinated nerve fibers in the human brain with age. J Comp Neurol 2003; 462(2): 144-52.
[44]
Meier-Ruge W, Ulrich J, Brühlmann M, Meier E. Age-related white matter atrophy in the human brain. Ann N Y Acad Sci 1992; 673: 260-9.
[45]
Mukhtar E, Adhami VM, Mukhtar H. Targeting microtubules by natural agents for cancer therapy. Mol Cancer Ther 2014; 13(2): 275-84.
[46]
Jordan MA. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr Med Chem Anticancer Agents 2002; 2(1): 1-17.
[47]
Tognaelli JM, Dawood M, Shariff MIF, et al. Magnetic resonance spectroscopy: principles and techniques: lessons for clinicians. J Clin Exp Hepatol 2015; 5(4): 320-8.
[48]
Gujar SK, Maheshwari S, Björkman-Burtscher I, Sundgren PC. Magnetic resonance spectroscopy. J Neuroophthalmol 2005; 25(3): 217-26.
[49]
Verma A, Kumar I, Verma N, Aggarwal P, Ojha R. Magnetic resonance spectroscopy-revisiting the biochemical and molecular milieu of brain tumors. BBA Clin 2016; 5: 170-8.
[50]
Lin AQ, Shou JX, Li XY, Ma L, Zhu XH. Metabolic changes in acute cerebral infarction: findings from proton magnetic resonance spectroscopic imaging. Exp Ther Med 2014; 7(2): 451-5.
[51]
Dani KA, An L, Henning EC, Shen J. On behalf of the national institute of neurological disorders and stroke natural history of stroke investigators s. multivoxel mr spectroscopy in acute ischemic stroke: comparison to the stroke protocol MRI. Stroke 2012; 43(11): 2962-7.
[52]
Gröger A, Kolb R, Schäfer R, Klose U. Dopamine reduction in the substantia nigra of parkinson’s disease patients confirmed by in vivo magnetic resonance spectroscopic imaging. PLOS ONE 2014; 9(1)e84081
[53]
Gao F, Barker PB. Various MRS application tools for alzheimer disease and mild cognitive impairment. AJNR 2014; 35(6): 4-11.
[54]
Murray ME, Przybelski SA, Lesnick TG, et al. Early Alzheimer’s disease neuropathology detected by proton mr spectroscopy. J Neurosci 2014; 34(49): 16247-55.
[55]
Wilson M, Cummins CL, MacPherson L, et al. Magnetic resonance spectroscopy metabolite profiles predict survival in paediatric brain tumours. Eur J Cancer 2013; 49(2): 457-64.
[56]
Wilson M, Cummins CL, MacPherson L, et al. Magnetic resonance spectroscopy metabolite profiles predict survival in paediatric brain tumours. Eur J Cancer 2013; 49(2): 457-64.
[57]
Hu Q, Khanna P, Ee Wong BS, et al. Oxidative stress promotes exit from the stem cell state and spontaneous neuronal differentiation. Oncotarget 2018; 9(3): 4223-38.
[58]
He L, He T, Farrar S, Ji L, Liu T, Ma X. Antioxidants maintain cellular redox homeostasis by elimination of reactive oxygen species. Cell Physiol Biochem 2017; 44: 532-53.
[59]
Brown S, Dennis A, et al. Further structure–activity relationships study of substituted dithiolethiones as glutathione-inducing neuroprotective agents. Chem J Central 2016; 10: 64.
[60]
Dringen R, Pfeiffer B, Hamprecht B. Synthesis of the antioxidant glutathione in neurons: supply by astrocytes of CysGly as precursor for neuronal glutathione. J Neurosci 1999; 19(2): 562-9.
[61]
Meister A. Biosynthesis and functions of glutathione, an essential biofactor. J Nutr Sci Vitaminol 1992; 8: 1-6.
[62]
Aoyama K, Nakaki T. Impaired glutathione synthesis in neurodegeneration. Int J Mol Sci 2013; 14(10): 21021-44.
[63]
Mar´ıM MA, Colell A, Garc’ıa-Ruiz C, Ferna’ndez-Checa JC. Mitochondrial glutathione, a key survival antioxidant. Antioxid Redox Signal 2009; 11: 2685-700.
[64]
Mandal PKSS. Brain oxidative stress: detection and mapping of antioxidant marker “Glutathione” in different brain regions of healthy male/female, MCI and Alzheimer patients using non-invasive magnetic resonance spectroscopy. Biochem Biophys Res Commun 2012; 417(1): 43-8.
[66]
Srinivasan R, Ratiney H, Hammond-Rosenbluth KE, Pelletier D, Nelson SJ. MR spectroscopic imaging of glutathione in the white and gray matter at 7 T with an application to multiple sclerosis. Magn Reson Imaging 2010; 28(2): 163-70.
[67]
Choi IY, Lee SP, Denney DR, Lynch SG. Lower levels of glutathione (GSH) in the brains of secondary progressive multiple sclerosis patients measured by 1h magnetic resonance chemical shift imaging at 3 T. Multiple Sclerosis 2011; 17(3): 289-96.
[68]
Paling D, Golay X, Wheeler-Kingshott C, Kapoor R, Miller D. Energy failure in multiple sclerosis and its investigation using MR techniques. J Neurol 2011; 258(12): 2113-27.
[69]
Grossman RI, Ramer KN, Gonzalez-Scarano F, Cohen JA. MR proton spectroscopy in multiple sclerosis. AJNR Am J Neuroradiol 1992; (13): 1535-43.
[70]
Arnold DLMP, Francis GS, O’Connor J, Antel JP. Proton magnetic resonance spectroscopic imaging for metabolic characterization of demyelinating plaques. Ann Neurol 1992; 31: 235-41.
[71]
Davie CA. Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain 1994; 49-58.
[72]
Silver MD. Proton magnetic resonance spectroscopy in a pathologically confirmed acute demyelinating lesion. J Neurol 1997; 244: 204-7.
[73]
Simone ILTM. High resolution proton MR spectroscopy of cerebrospinal fluid in MS patients. Comparison with biochemical changes in demyelinating plaques. J Neurol Sci 144(1-2): 182-90.
[74]
Amorini AMPA. Serum lactate as a novel potential biomarker in multiple sclerosis. Biochim Biophys Acta 2014; 1842(7): 1137-43.
[75]
Timm WM. Assessing oxidative stress in tumors by measuring the rate of hyperpolarized [1- 13c] dehydroascorbic acid reduction using 13c magnetic resonance spectroscopy. J Biol Chem 2017; 292(5): 1737-48.
[76]
Barker PB, Bryan RN. In vivo magnetic resonance spectroscopy of human brain tumors. Top Magn Reson Imaging 1993; 5: 32-45.
[77]
Poptani H, Pandey R, Jain VK, Chhabra DK. Characterization of intracranial mass lesions with in vivo proton MR spectroscopy. Am J Neuroradiol 1995; 16: 1593-603.
[78]
Usenius JPVP. Quantitative metabolite patterns of human- brain tumors: detection by 1H NMR spectroscopy in vivo and in vitro. J Comput Assist Tomogr 1994; 18: 705-13.
[79]
Guillevin TS. Predicting the outcome of grade II glioma- treated with temozolomide using proton magnetic resonance spectroscopy. Br J Cancer 2011; 104: 1854-61.
[80]
Ben-Yoseph RB. Oxidation therapy: the use of a reactive oxygen species-generating enzyme system for tumour treatment. Br J Cancer 1994; (70): 1131-5.
[81]
Kitamura HM. Oxidative stress markers and phosphorus magnetic resonance spectroscopy in a patient with GLUT1 deficiency treated with modified Atkins diet. Brain Dev 2012; 34(5): 372-5.
[82]
Ashbuner JFK. Voxel-based morphometry–the methods. Neuroimage 2000; 11: 1-805.
[83]
Wright IC MP, Poline JB, et al. A voxel-based method for the statistical analysis of gray and white matter density applied to schizophrenia. Neuroimage 1995; 2: 244-52.
[84]
Wright IC, Ellison ZR, Sharma T, Friston KJ, Murray RM, McGuire PK. Mapping of grey matter changes in schizophrenia. Schizophr Res 1999; 35: 1-14.
[85]
Lin WC, Chou KH, Lee PL, et al. Brain mediators of systemic oxidative stress on perceptual impairments in Parkinson’s disease. J Transl Med 2015; 13: 386.
[86]
Townsend DW. Positron emission tomography/computed tomography. Nuclear Med 2008; 38(3): 152-66.
[87]
Tuominen L, Nummenmaa L. Mapping neurotransmitter networks with PET: an example on serotonin and opioid systems. Hum Brain Mapp 2014; 35(5): 1875-84.
[88]
Brooks DJ. Imaging approaches to parkinson disease. J Nucl Med 2010; 51(4): 596-609.
[89]
Sarikaya I. PET imaging in neurology: Alzheimer’s and Parkinson’s diseases. Nucl Med Commun 2015; 36: 775-81.
[90]
Loane C, Politis M. Positron emission tomography neuroimaging in Parkinson’s disease. Am J Transl Res 2018; 4: 323-41.
[91]
Whone AL, Watts RL, Stoess l AJ, et al. Slower progression of Parkinson’s disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurology 2003; 54(1): 93-101.
[92]
Ikawa M, Okazawa H, Kudo T, Kuriyama M, Fujibayashi Y, Yoneda M. Evaluation of striatal oxidative stress in patients with Parkinson’s disease using [62Cu] ATSM PET. Nuclear Med Biol 2011; 38(7): 945-51.
